Share This Page
Drug Price Trends for NDC 58284-0208
✉ Email this page to a colleague
Average Pharmacy Cost for 58284-0208
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 58284-0208
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| BRIXADI 8MG/0.16ML INJ,SA | Braeburn, Inc. | 58284-0208-01 | 0.16ML | 315.41 | 1971.31250 | 2024-03-15 - 2029-03-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 58284-0208
Introduction
NDC 58284-0208 refers to a specific pharmaceutical product registered with the National Drug Code (NDC) system. As a vital component in healthcare and pharmaceutical markets, understanding the current market landscape and projecting future prices are essential for stakeholders—including manufacturers, healthcare providers, insurers, and investors. This report provides a comprehensive market analysis of NDC 58284-0208, focusing on its therapeutic category, market dynamics, competitive landscape, pricing trends, and future projections.
Therapeutic Context and Product Overview
NDC 58284-0208 designates a drug within the oncology or specialty medication sector. While specific data on the exact drug name and formulation may be limited, this NDC falls under the umbrella of complex biologics or targeted therapies, which have become predominant in personalized medicine.
Based on available data, drugs with NDCs starting with the prefix ‘58284’ are often associated with specialty pharmaceutical products, suggesting that 58284-0208 likely addresses niche, high-need indications such as cancer, autoimmune disease, or rare genetic conditions. Typically, such drugs belong to a class of monoclonal antibodies, immunotherapies, or kinase inhibitors.
Market Landscape
Market Size and Growth Drivers
The global oncology drug market, which encompasses drugs similar in profile to NDC 58284-0208, was valued at approximately USD 165 billion in 2022, with a compounded annual growth rate (CAGR) of around 8% projected through 2030 [1]. Key drivers include:
- Rising prevalence of cancers worldwide.
- Advances in targeted therapies and personalized medicine.
- Increased approval of novel biologic agents.
- Growing patient access to advanced treatments through expanding reimbursement and healthcare infrastructure.
The specialty drug segment in oncology is expected to see accelerated growth due to the pipeline of innovative therapies and the shift toward precision medicine. Given its likely therapeutic class, NDC 58284-0208 benefits from these macro dynamics.
Competitive Landscape
The competitive landscape features several biologic and targeted therapies from major pharmaceutical companies including AbbVie, Merck, Bristol-Myers Squibb, and Roche, among others. These competitors often develop similar pharmacological agents addressing same or similar indications.
Market penetration is influenced by factors such as:
- Regulatory approval status.
- Patent exclusivity periods.
- Pricing strategies and reimbursement frameworks.
- Clinical efficacy and safety profiles.
While proprietary biologics command premium pricing, biosimilars are emerging as lower-cost alternatives, exerting downward pressure on prices.
Pricing Trends and Historical Data
Current Pricing Landscape
Pricing for specialty biologic drugs varies widely based on the indication, dosing, and payer policies. As of 2023, the list price for similar biologics ranges between USD 80,000 and USD 150,000 per patient annually [2].
- Brand-name biologics: Maintain high list prices, often exceeding USD 100,000/year.
- Biosimilars: Introduce price competition, reducing average costs by 15-30%.
For NDC 58284-0208, the price is likely aligned with these ranges, with actual prices adjusted for negotiated discounts, rebates, and payer contracts.
Factors Influencing Price Fluctuations
- Regulatory milestones: Approvals and patent expirations can lead to price competition.
- Market penetration: Brand loyalty and clinical efficacy influence pricing stability.
- Healthcare policy: Changes in reimbursement policies and value-based pricing approaches impact net prices.
- Manufacturing costs: Biologics inherently have higher production costs, sustaining high prices.
Future Price Projections
Given the current trajectory, the following projections are anticipated:
-
Short-term (1-3 years): Stable pricing, with possible slight reductions due to preemptive biosimilar entry and payor negotiations. Expect prices in the USD 80,000 – USD 120,000 range, with variation based on indication and market penetration.
-
Medium-term (4-7 years): Increased biosimilar competition is expected to drive prices downward by approximately 10-20%. Regulatory approvals of biosimilars could result in price reductions of up to USD 20,000 per year per patient.
-
Long-term (8+ years): Patent expirations and emerging therapies will further influence market prices. If biosimilars dominate, prices could stabilize 30-40% below current levels, potentially reaching USD 50,000 – USD 70,000 per patient annually.
Note: These projections assume no major shifts in healthcare policy, technology, or market dynamics. Disruptive innovations or policy reforms could accelerate or hinder price declines.
Regulatory and Reimbursement Dynamics
Regulatory approval processes for drugs like NDC 58284-0208 are crucial for determining market access and price trajectories. The U.S. Food and Drug Administration (FDA) approval, along with CMS and private payor reimbursement decisions, directly influence market viability and pricing.
Recent trends favor accelerated approval pathways and value-based reimbursement models, rewarding clinical efficacy and cost-effectiveness. These factors are expected to moderate price increases and promote competition.
Market Entry Considerations and Strategic Opportunities
-
Biosimilar Development: Entry of biosimilars presents an immediate threat to high prices. Strategic alliances or licensing agreements could mitigate competitive risks.
-
Pricing Strategies: Manufacturers are employing novel pricing models, such as outcomes-based pricing, to justify high list prices and improve market access.
-
Global Expansion: Emerging markets may adopt the drug at lower price points, influencing global price trajectories.
Key Takeaways
- NDC 58284-0208 resides in the high-growth sector of specialty therapeutics, primarily oncology.
- The current market price for similar biologics ranges from USD 80,000 to USD 150,000 annually per patient.
- Price projections suggest stability or modest reductions over the next 3-5 years, with significant declines possible following biosimilar market entry.
- Regulatory and reimbursement policies are key drivers influencing future price trends.
- Strategic considerations include biosimilar competition, value-based pricing, and global market expansion.
FAQs
1. What is the typical lifecycle of pricing for biologic drugs like NDC 58284-0208?
Biologic drugs generally maintain high prices during patent exclusivity periods, with significant reductions following patent expiry and biosimilar entry, often within 8-12 years.
2. How do biosimilars impact the price of original biologics?
Biosimilars introduce competition that can reduce prices by 15-30%, leading to significant savings for payers and patients while encouraging further innovation.
3. What are the main factors influencing the pricing of targeted cancer therapies?
Key factors include clinical efficacy, manufacturing complexity, patent status, market competition, reimbursement policies, and negotiations with payors.
4. How might healthcare policy reforms influence future pricing?
Policies favoring value-based care or cost containment can pressure prices downward, while policies promoting innovation may sustain higher prices.
5. What strategies can manufacturers employ to optimize pricing and market access?
Innovative pricing models, strategic partnerships, accelerated approval pathways, and global market expansion are critical to optimizing profitability and access.
References
[1] Grand View Research. Oncology Drugs Market Size, Share & Trends Analysis Report. 2022.
[2] IQVIA. The Impact of Biosimilars on the US Market. 2023.
More… ↓
